News
First in Human PyCath
We are proud to announce that PyCath has officially moved from preclinical validation to its first use in patients.
This marks a historic moment for Medyria and for coronary physiology, as real-world physiological data were acquired in humans using our microcatheter for the very first time.
Medyria - Khayrulla Mirzakarimov
🌍 Swiss technology, global impact.
At Medyria, we design cardiovascular devices that combine precision, usability and adaptability.
We believe that advanced diagnostics should be accessible to clinicians everywhere, not just in high-resource settings.
Medyria - Masahiro Hada
🔬 Precision and simplicity, with the promise of something bigger
At Medyria, we believe that true innovation removes barriers rather than adding complexity.
We design devices that enhance diagnostic clarity and fit seamlessly into existing workflows.
Medyria - Saidamir Djafarov
💡 Making innovation usable, anywhere in the world
After months of collaboration, validation and technical refinement, we are ready to take the next step. This achievement brings us closer to delivering real clinical value in the field of interventional cardiology.
Medyria - Alessandro Candreva
🧪 Three parameters. One catheter. Simple, precise, revolutionary.
At Medyria, we’re committed to simplifying complex decision-making in interventional cardiology.
We develop tools that provide complete, high-quality physiological data while integrating naturally into existing workflows.
Medyria - Carlos Collet
🚀 PyCath: ready for first-in-human validation!
We’re thrilled to announce the completion of the preclinical phase for our PyCath microcatheter, a true breakthrough in coronary physiology.
Medyria’s mission: advancing cardiovascular care with innovative tools for precise diagnosis and treatment of microvascular and epicardial diseases.
Medyria presents at LSI
Medyria presented at the LSI conference.
LSI exists to bridge the relationship and knowledge gap between emerging companies, investors, and major corporations.
Medyria appoints new Director : William Little
Mr. Little brings over 20 years of medical device marketing and commercial experience in interventional cardiology having served in leadership roles at Abbott Vascular, St. Jude Medical, Bard, and Boston Scientific. He currently serves as Chief Operating Officer at Neovasc, a company disrupting the field of refractory angina focused on improving coronary physiology and alleviating chest pain. As DVP of Global Marketing, and Head of Customer and New Market Insights at Abbott Vascular, Mr. Little was responsible for products accounting for $3B in annual global revenue. While at St. Jude Medical, Mr. Little oversaw the Interventional Cardiology and Structural Heart franchises including the imaging and physiology businesses. Mr. Little began his medical device career and spent 13 years at Boston Scientific.
PyCath presented at the EuroPCR Innovators days
Dr. Candreva from the University Hospital of Zürich presented the pre-clinical experience with the PyCath system.
Innosuisse project granted
Very proud to announce that the Innosuisse project PyC+ "Enhanced blood flow and pressure measurements with PhysioCath- microcatheter for reliable diagnosis of 'Ischemia with Non-Obstructive Coronary Artery' (INOCA)" was accepted for a grant. This will allow the consortium formed by The University Hospital of Zürich, CardioCantro Ticino, ZHAW and Medyria to bring forward the PhysioCath project through further technical development and pre-clinical validation. We are really looking forward to starting this journey.